Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vidoflufolastat (18F)
- Development stage
- Phase 3
- Lead developer
- Novartis
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Vidoflufolastat (18F) is a fluorine-18 labeled radiopharmaceutical diagnostic imaging agent developed by Novartis for the detection and localization of prostate cancer. It is a small molecule PET radiotracer that utilizes a phosphoramidate scaffold to bind pseudo-irreversibly to the prostate-specific membrane antigen (PSMA) with high nanomolar affinity. PSMA is a transmembrane protein that is significantly overexpressed in the majority of prostate cancer cells, including metastatic and castrate-resistant forms. By targeting PSMA, vidoflufolastat (18F) enables high-resolution positron emission tomography (PET) imaging of PSMA-positive tumors. The agent has been evaluated in Phase 3 clinical trials, including the GuideView study for newly diagnosed high-risk prostate cancer and the GuidePath study for patients with biochemical recurrence, demonstrating high sensitivity and specificity for lesion detection.
- Other names
- vidoflufolastat F-18fluorine-18 vidoflufolastatfluorine18 vidoflufolastatfluorine 18 vidoflufolastat
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on vidoflufolastat (18F).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vidoflufolastat (18F).